Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Orion Oyj
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
September 26, 2024
From
Orion Oyj
Via
GlobeNewswire
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
September 25, 2024
From
Orion Oyj
Via
GlobeNewswire
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
September 16, 2024
From
Orion Oyj
Via
GlobeNewswire
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
July 17, 2024
From
Orion Oyj
Via
GlobeNewswire
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 01, 2024
From
Orion Oyj
Via
GlobeNewswire
Orion is developing the Finnish life science industry in a unique collaboration project
June 03, 2024
From
Orion Oyj
Via
GlobeNewswire
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
January 26, 2024
From
Orion Oyj
Via
GlobeNewswire
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
January 08, 2024
From
Orion Oyj
Via
GlobeNewswire
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
January 05, 2024
From
Orion Oyj
Via
GlobeNewswire
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
December 27, 2023
From
Orion Oyj
Via
GlobeNewswire
Orion Research Foundation grants EUR 1,112,000 for research in 2024
November 15, 2023
From
Orion Oyj
Via
GlobeNewswire
European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder
July 31, 2023
From
Orion Oyj
Via
GlobeNewswire
Orion and Bayer expand clinical development program for darolutamide in prostate cancer
March 23, 2023
From
Orion Oyj
Via
GlobeNewswire
Darolutamide approved for additional prostate cancer indication in China
March 20, 2023
From
Orion Oyj
Via
GlobeNewswire
Darolutamide receives EU approval for additional indication in prostate cancer
March 01, 2023
From
Orion Oyj
Via
GlobeNewswire
Darolutamide receives approval for additional prostate cancer indication in Japan
February 27, 2023
From
Orion Oyj
Via
GlobeNewswire
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
January 27, 2023
From
Orion Oyj
Via
GlobeNewswire
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
January 04, 2023
From
Orion Oyj
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.